31st Jan 2013 15:04
The pharmaceuticals and biotechnology sector was at the bottom of the pile on Thursday after a disappointing set of full-year results from AstraZeneca weighed on share prices. The company, which manufactures drugs to treat range of cardiovascular conditions, reported a 15% fall in revenue at consta
Read more31st Jan 2013 08:23
Specialist healthcare company BTG said Thursday it expects full-year revenues at the 'top end' of it guidance following strong trading of the group's medical products. The FTSE 250 business said the last three months have wielded positive results, particularly from acute care items. The board anti
Read more